HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

5-HT3 Serotonin Receptors (5 HT3 Receptor)

Subscribe to New Research on 5-HT3 Serotonin Receptors

A subclass of serotonin receptors that form cation channels and mediate signal transduction by depolarizing the cell membrane. The cation channels are formed from 5 receptor subunits. When stimulated the receptors allow the selective passage of SODIUM; POTASSIUM; and CALCIUM.

Also Known As:

5 HT3 Receptor; Receptors, Serotonin, 5-HT3; 5-HT3 Receptor; 5-Hydroxytryptamine-3 Receptor; Receptor, Serotonin 3; Receptor, Serotonin, 5-HT3 Subunit A; Receptor, Serotonin, 5-HT3 Subunit B; Receptor, Serotonin, 5-HT3 Subunit C; Receptor, Serotonin, 5-HT3 Subunit D; Receptor, Serotonin, 5-HT3 Subunit E; Receptor, Serotonin, 5-HT3A; Receptor, Serotonin, 5-HT3B; Receptor, Serotonin, 5-HT3C; Receptor, Serotonin, 5-HT3D; Receptor, Serotonin, 5-HT3E; Serotonin 3 Receptors; 5 Hydroxytryptamine 3 Receptor; Receptor, 5-Hydroxytryptamine-3; Receptors, Serotonin 3; Serotonin 3 Receptor

Networked: 669 relevant articles (108 outcomes, 104 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 90489
  - Carrier Proteins: 11456
    - Membrane Transport Proteins: 165
      - Ion Channels: 3653
        Ligand-Gated Ion Channels: 82
        Cysteine Loop Ligand-Gated Ion Channel Receptors: 3
        5-HT3 Serotonin Receptors: 669
        human HTR3A protein
        human HTR3B protein
        human HTR3C protein
        human HTR3D protein
        human HTR3E protein
        mouse Htr3a protein
  - Membrane Proteins: 5300

Experts

1.	Müller, W: 17 articles (10/2006 - 01/2000)
2.	Stratz, T: 14 articles (10/2006 - 01/2000)
3.	Navari, Rudolph M: 8 articles (10/2015 - 07/2003)
4.	Trissel, Lawrence A: 6 articles (01/2009 - 02/2005)
5.	Trusley, Craig: 5 articles (01/2009 - 11/2007)
6.	Kupiec, Thomas C: 5 articles (01/2009 - 11/2007)
7.	Späth, M: 5 articles (01/2004 - 01/2000)
8.	Mousavizadeh, Kazem: 4 articles (12/2015 - 06/2008)
9.	Cox, David: 4 articles (07/2014 - 08/2011)
10.	Rudd, John A: 4 articles (03/2014 - 07/2003)

Related Diseases

1.	Vomiting 08/01/2014 - "Acute emesis has largely been alleviated with the use of 5-HT3 receptor antagonists, while an improvement in preventing delayed emesis has been achieved with NK1 receptor antagonists. " 11/01/1995 - "However, with the development of basic research on the mechanisms of vomiting, each 5-HT3 receptor antagonist has appeared to have different pharmacological actions and, subsequently, the difference in the clinical efficacy of each drug has been reported in Europe and USA. " 07/01/2000 - "Studies have yielded conflicting results concerning the use of 5-HT3 receptor antagonists alone in delayed emesis. " 06/01/1996 - "Further studies in animals have provided valuable information relating to the pathophysiology of emesis and the mechanism of action of 5-HT3 receptor antagonists. " 02/01/1990 - "In view of the widespread use of the ferret in studies of emesis and particularly in the characterization of the antiemetic actions of 5-HT3 receptor antagonist, the opportunity is taken to assess the suitability of this species for studies of emesis. "
2.	Nausea 07/01/2000 - "The enhancement of NK1 receptor antagonist antiemetic activity through combination with a 5-HT3 receptor antagonist is not replicated in motion-induced nausea." 02/01/1996 - "Several basics are investigated and depending on this knowledge some special treatment strategies have been developed (5-HT3-receptor-antagonists in the treatment of nausea, Figure 1, Table 2). " 07/01/1999 - "The 5-HT3 receptor antagonists are the most effective agents against chemotherapy-induced nausea and should become standard antiemetic therapy for high-risk patients. " 05/15/2003 - "The 5-HT3 receptor antagonists are effective for preventing nausea and vomiting from these causes. " 06/01/2011 - "The 5-HT3 receptor is one of a number of receptors that play a role in mediating nausea and vomiting, and as such, 5-HT3 receptor antagonists demonstrate the greatest anti-emetic efficacy when administered in combination with other drug classes."
3.	Postoperative Nausea and Vomiting (PONV) 01/01/2007 - "The purpose of this meta-analysis was to assess the efficacy of prophylactic administration of 5-HT3 receptor antagonists for postoperative nausea and vomiting in neurosurgical patients at 24 and 48+ hours. " 01/01/2007 - "Despite the ability of 5-HT3 receptor antagonists to reduce emetic episodes, future investigations should seek to address the control of postoperative nausea and to reduce further postoperative emesis in this population." 06/01/2006 - "A brief overview of the incidence, risk factors and current management recommendations for PONV and current controversies with special emphasis on the 5-HT3 receptor antagonists, is discussed." 01/01/2006 - "The role of 5-HT3 receptor antagonists in preventing postoperative nausea and vomiting." 02/01/2003 - "We conclude that the risk of postoperative nausea and vomiting remained high in this setting despite 5-HT3 receptor antagonist prophylaxis and that the choice between these agents should be based on the lowest available acquisition cost."
4.	Neoplasms (Cancer) 04/01/2015 - "Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter." 05/01/1998 - "Antiemetic efficacy of subcutaneous 5-HT3 receptor antagonists in terminal cancer patients." 10/15/2006 - "The objective of this study is to evaluate the ECG changes after administration of 5-HT3 receptor antagonists and chemotherapeutic agents in children with cancer. " 09/01/2005 - "However, due to patient exclusion criteria, such trials with 5-HT3 receptor antagonists may have failed to examine the risk of these agents in "real world" patients with cancer. " 08/01/2004 - "Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients."
5.	Pain (Aches) 09/24/2015 - "Spinal 5-HT3 receptor (5-HT3R) has been implicated in chronic pain development. " 01/01/2014 - "However, the mechanisms underlying the activation of the 5-HT3 receptor and its contribution to facilitation of pain remain unclear. " 02/01/2007 - "[Antinociceptive properties of the 5-HT3 receptor antagonist in the model of inflammatory pain in rats of different age with prenatal deficit of serotonine and under stress]." 12/22/2000 - "The 5-HT3 receptor may therefore be involved in the mediation of TMJ pain in systemic inflammatory joint disorders." 12/01/1996 - "This distribution implies that some 5-HT3 receptor antagonists might reduce certain symptoms of IBS, such as pain, by reducing the reactivity of the visceral afferent neurones linking the gut with the brain and spinal cord. "

Related Drugs and Biologics

1.	Ondansetron (Zofran)
2.	Cisplatin (Platino)
3.	Dexamethasone (Maxidex)
4.	Granisetron (Kytril)
5.	tropisetron (Navoban)
6.	palonosetron (Aloxi)
7.	Serotonin (5 Hydroxytryptamine)
8.	alosetron (Lotronex)
9.	aprepitant (Emend)
10.	azasetron

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Craniotomy
3.	Radiotherapy
4.	Adjuvant Chemotherapy
5.	Fluid Therapy (Oral Rehydration Therapy)